参考文献
[1]Mahler M, Raijmakers R.Novel aspects of autoantibodies to the PM/Scl complex: clinical, genetic and diagnostic insights[J].Autoimmunity
reviews, 2007, 6(7): 432—437.
[2]Hanke K, Brückner CS, Dähnrich C, et al.Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for diあ erent subsets of
systemic sclerosis patients[J].Arthritis research & therapy, 2009, 11(1): R22.
[3]Koschik RW 2nd, Fertig N, Lucas MR, et al.Anti-PM-Scl antibody in patients with systemic sclerosis[J].Clin Exp Rheumatol, 2012, 30(2 Suppl 71): S12—S16.
[4]Kurki P, Vanderlaan M, Dolbeare F, et al.Expression of proliferating cell nuclear antigen (PCNA)/cyclin during the cell cycle[J].Experimental
cell research, 1986, 166(1): 209—219.
[5]Mitri GM, Lucas M, Fertig N, et al.A comparison between anti-Th/To-and anticentromere antibody-positive systemic sclerosis patients with
limited cutaneous involvement[J].Arthritis & Rheumatism, 2003, 48(1): 203—209.
[6]Mahler M, Hudson M, Bentow C, et al.Autoantibodies to stratify systemic sclerosis patients into clinically actionable subsets[J].Autoimmunity
reviews, 2020: 102583.
[7]Ceribelli A, Satoh M, Chan EK.A new immunoprecipitation-real time quantitative PCR assay for anti-Th/To and anti-U3RNP antibody detection
in systemic sclerosis[J].Arthritis research & therapy, 2012, 14(3): R128.
[8]Ulanet DB, Wigley FM, Gelber AC, et al.Autoantibodies against B23, a nucleolar phosphoprotein, occur in scleroderma and are associated with pulmonary hypertension[J].Arthritis Care & Research: Oき cial Journal of the American College of Rheumatology, 2003, 49(1): 85—92.
[9]Deng JS, Ballou B, Hofmeister JK.Internalization of anti-nucleolin antibody into viable HEp—2 cells[J].Molecular biology reports, 1996,23(3—4): 191—195.
[10]Palmieri D, Richmond T, Piovan C, et al.Human anti-nucleolin recombinant immunoagent for cancer therapy[J].Proceedings of the National Academy of Sciences, 2015, 112(30): 9418—9423.
[11]Jarjour WN, Minota S, Roubey RA, et al.Autoantibodies to nucleolin cross-react with histone H1 in systemic lupus erythematosus[J].Molecular biology reports, 1992, 16(4): 263—266.
[12]Van Eenennaam H, Vogelzangs JH, Bisschops L, et al.Autoantibodies against small nucleolar ribonucleoprotein complexes and their clinical associations[J].Clinical & Experimental Immunology, 2002, 130(3): 532—540.
[13]Stochmal A, Czuwara J, Trojanowska M, et al.Antinuclear antibody in systemic sclerosis: an update[J].Clinical Reviews in Allergy &Immunology, 2020, 58(1): 40—51.
[14]Harvey GR, Butts S, Rands AL, et al.Clinical and serological associations with anti-RNA polymerase antibody in systemic sclerosis[J].Clinical and experimental immunology, 1999, 117(2): 395.
[15]Shah AA, Laiho M, Rosen A, et al.Protective eあ ect against cancer of antibody to the large subunits of both RNA polymerases I and III in scleroderma[J].Arthritis & Rheumatology, 2019, 71(9): 1571—1579.
[16]Bunn CC, Denton CP, Shi-Wen X, et al.Anti-RNA polymerases and other autoantibody specif icities in systemic sclerosis[J].British journal of rheumatology, 1998, 37(1): 15—20.
[17]Shoenfeld, Y, Meroni, PL, Gershwin ME, et al.Autoantibodies[M].3rd.Amsterdam: Elsevier 2014.